Akebia Therapeutics, Inc.
NASDAQ:AKBA
3.13 (USD) • At close September 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Revenue
| 160.18 | 194.623 | 292.602 | 213.578 | 295.307 |
| Cost of Revenue
| 63.177 | 74.149 | 84.796 | 153.394 | 295.908 |
| Gross Profit
| 97.003 | 120.474 | 207.806 | 60.184 | -0.601 |
| Gross Profit Ratio
| 0.606 | 0.619 | 0.71 | 0.282 | -0.002 |
| Reseach & Development Expenses
| 37.652 | 63.079 | 129.114 | 147.852 | 218.485 |
| General & Administrative Expenses
| 101.945 | 0 | 131.901 | 165.94 | 149.099 |
| Selling & Marketing Expenses
| 4.6 | 100.233 | 6.7 | 8.2 | 5 |
| SG&A
| 106.545 | 100.233 | 138.601 | 174.14 | 154.099 |
| Other Expenses
| 40.308 | 3.418 | -12.541 | 3.489 | 3.409 |
| Operating Expenses
| 184.505 | 166.73 | 270.988 | 325.502 | 375.841 |
| Operating Income
| -50.472 | -46.256 | -63.182 | -265.318 | -376.442 |
| Operating Income Ratio
| -0.315 | -0.238 | -0.216 | -1.242 | -1.275 |
| Total Other Income Expenses Net
| -18.938 | -5.669 | -13.447 | -17.522 | -5.631 |
| Income Before Tax
| -69.41 | -51.925 | -92.562 | -282.84 | -383.457 |
| Income Before Tax Ratio
| -0.433 | -0.267 | -0.316 | -1.324 | -1.299 |
| Income Tax Expense
| 0 | 0 | 13.447 | -37.97 | -33.59 |
| Net Income
| -69.41 | -51.925 | -106.009 | -244.87 | -349.867 |
| Net Income Ratio
| -0.433 | -0.267 | -0.362 | -1.147 | -1.185 |
| EPS
| -0.33 | -0.28 | -0.58 | -1.48 | -2.53 |
| EPS Diluted
| -0.33 | -0.28 | -0.58 | -1.48 | -2.53 |
| EBITDA
| -13.721 | -6.868 | -43.259 | -225.96 | -340.996 |
| EBITDA Ratio
| -0.086 | -0.035 | -0.148 | -1.058 | -1.155 |